## UTILITY PATENT APPLICATION **TRANSMITTAL**

Please type a plus sign (+) inside this box

Attorney Docket No.		16U 102 R1			
First Inventor		Shu et al.			
Title	Human EphA6 Gene and Polypeptide				

(Only for new nonprovision	nal applications under 37 CFR 1.53(b))	Express	Mail Label No.			<i>_</i>	
APPLICA	1	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application					
	erning utility patent application contents	3.		ashington, I			
	orm (e.g., PTO/SB/17) duplicate for fee processing)	7.	CD-ROM or CD-R			table or	
Applicant claims s		8. Nuc	Computer Program			ıbmission	
See 37 CFR 1.27.	Total Pages 49 1		applicable, all necessa				
3. Specification (preferred arrangement	set forth below)	а. [	x Computer Reada	ble Form (0	CRF)		
- Descriptive title	of the invention e to Related Applications	b.	Specification Sequenc	e Listing or	1:		
- Statement Rega	arding Fed sponsored R & D		i. CD-ROM or CD-R (2 copies); or				
	quence listing, a table, rogram listing appendix		ı i. 🛛 paper				
- Background of		c.	x Statements verify	ying identity	of abo	ove copies	
- Brief Summary	of the Invention n of the Drawings (if filed)		CCOMPANYING	APPLIC	ATIO	N PARTS	
- Detailed Descri		9.	Assignment Pape				
- Claim(s)	Diaglogyro		37 CFR 3.73(b) S	tatement	Y	Power of	
- Abstract of the	Disclosure	10. [	(when there is an	• ,		Attorney	
4. 4 Drawing(s) (35 U	S.C. 113) [Total Sheets 8	] [11.	English Translation		nt (if ap		
5. Oath or Declaration	յ 12.	12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations					
a. X Newly executed (original or copy)			Preliminary Ame	ndment			
Copy from a prior application (37 CFR 1.63 (d)) b. (for continuation/divisional with Box 18 completed)			Return Receipt Postcard (MPEP 503) (Should be specifically itemized)				
i. DELETION OF INVENTOR(S)			15. Certified Copy of Priority Document(s) (if foreign priority is claimed)				
	Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR			Monaublication Poquest under 3511 S.C. 122			
	1 63(d)(2) and 1.33(b) (b)(2)(B)(i). Applicant must attach form PTO/SB/35				orm PTO/SB/35		
6. Application Data	Sheet See 37 CFR 1 76	1.7.5	or its equivalent.				
	6. Application Data Sheet. See 37 CFR 1.76						
	CATION, check appropriate box, and su	ipply the requ	iisite information belov	v and in a p	relimin	ary amendment,	
or in an Application Data She	Divisional Continuation-in-part (CIF	۸ (۱	of prior application No :	,			
Prior application information	Examiner	,	Group Art Unit				
For CONTINUATION OR DIVISI	ONAL APPS only: The entire disclosure of	the prior app	lication, from which an	oath or decl	aration	is supplied under	
Box 5b, is considered a part of	the disclosure of the accompanying cont	inuation or div	risional application and	is hereby in	corpora	ated by reference.	
The incorporation <u>can only</u> be relied upon when a portion has been inadvertently omitted from the submitted application parts.  19. CORRESPONDENCE ADDRESS							
X Customer Number or Bar Co	de Label (Insert Custon 1, 15), inc. 1	er inde tabel he	ere) or	Correspon	dence add	dress below	
Name	0 ( 4 0 <sup>Ri</sup>	çhard M. Lebo	vitz		**	<u> </u>	
	<del>2640(</del>	)————					
Addross	PATENT_TRADEMARK	OFFICE					
Address		State		Zip C	ode		
City				<del></del>			
Country	T	elephone		Fa	X		
Name (Print/Type)	Richard M. Lebovitz	Reg	istration No. (Attorne	ey/Agent)		37,067	
Signature	Mr			Date	Oc	tober 9, 2001	

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

PTO/SB/17 (11-00)

PTO/SB/17 (11-00)
Approved for use through 10/31/2002 OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision

TOTAL AMOUNT OF PAYMENT

£

3

Co		
Application Number		
Filing Date		
First Named Inventor	Shu et al.	
Examiner Name		
Group Art Unit		
Attorney Docket No.	16U 102 R1	

METHOD OF PAYMENT	FEE CALCULATION (continued)			
The Commissioner is hereby authorized to charge	3. ADDITIONAL FEES			
Indicated fees and credit any overpayments to	Large Small			
Deposit Account 501761	Entity Entity Fee Fee Fee Fee Fee Description	Fee Paid		
Number	Fee Fee Fee Fee Fee Description Code (\$) Code (\$)	. se i aiu		
Account Name OriGene Technologies, Inc.	105 130 205 65 Surcharge - late filing fee or oath			
X Charge Any Additional Fee Required Under 37 CFR 1.16 and 1 17	127 50 227 25 Surcharge - late provisional filing fee or cover sheet			
X Applicant claims small entity status.	139 130 139 130 Non-English specification			
See 37 CFR 1 27	147 2,520 147 2,520 For filing a request for ex parte reexamination			
2. Payment Enclosed:  Check Credit card Money Other	112 920* 112 920* Requesting publication of SIR prior to Examiner action			
FEE CALCULATION	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action			
	115 110 215 55 Extension for reply within first month			
1. BASIC FILING FEE Large Entity Small Entity	116 390 216 195 Extension for reply within second month			
Fee Fee Fee Fee Description	117 890 217 445 Extension for reply within third month			
Code (\$) Code (\$)	118 1,390 218 695 Extension for reply within fourth month			
101 710 201 355 Utility filing fee 370	128 1,890 228 945 Extension for reply within fifth month			
106 320 206 160 Design filing fee	119 310 219 155 Notice of Appeal			
107 490 207 245 Plant filing fee  108 710 208 355 Reissue filing fee	120 310 220 155 Filing a brief in support of an appeal			
	121 270 221 135 Request for oral hearing			
114 150 214 75 Provisional filing fee	138 1,510 138 1,510 Petition to institute a public use proceeding			
SUBTOTAL (1) (\$) 370	140 110 240 55 Petition to revive - unavoidable			
2. EXTRA CLAIM FEES	141 1,240 241 620 Petition to revive - unintentional			
Fee from Extra Claims below Fee Paid	142 1,240 242 620 Utılıty issue fee (or reissue)			
Total Claims 21 -20** = 1 X 9 = 9	143 440 243 220 Design issue fee			
Independent $\begin{bmatrix} 6 \\ -3^{**} \end{bmatrix} = \begin{bmatrix} 3 \\ 126 \end{bmatrix}$	144 600 244 300 Plant issue fee			
Claims Multiple Dependent	122 130 122 130 Petitions to the Commissioner			
	123 50 123 50 Processing fee under 37 CFR 1.17(q)			
Large Entity Small Entity	126 180 126 180 Submission of Information Disclosure Stmt			
Fee Fee Fee Fee Description Code (\$) Code (\$)	581 40 581 40 Recording each patent assignment per property (times number of properties)			
103 18 203 9 Claims in excess of 20 102 80 202 40 Independent claims in excess of 3	146 710 246 355 Filing a submission after final rejection (37 CFR § 1 129(a))			
104 270 204 135 Multiple dependent claim, if not paid				
109 80 209 40 ** Reissue ındependent claıms over original patent	examined (37 CFR § 1.129(b))			
110 18 210 9 ** Reissue claims in excess of 20	179 710 279 355 Request for Continued Examination (RCE)			
and over original patent	169 900 169 900 Request for expedited examination of a design application			
SUBTOTAL (2) (\$) 135	Other fee (specify)			
**or number previously paid, if greater; For Reissues, see above *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)				

SUBMITTED BY			Complete (if	Complete (if applicable)		
Name (Print/Type)	Righard M. Lebovitz	Registration No. (Attorney/Agent)	37,067	Telephone	240-620-0268	
Signature	Tay			Date	October 9, 2001	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SHU et al.

Serial No.:

Not Assigned

Examiner: Not Assigned

Filed:

October 3, 2001

Group Art Unit: Not Assigned

For:

Human EphA6 Gene and Polypeptide

## **SEQUENCE DISCLOSURE UNDER §1.821**

Assistant Commissioner of Patents Washington, DC 20231

Sir:

This application contains a nucleotide and amino acid sequence disclosure. The information recorded in computer readable form on the attached diskette is identical to the attached written sequence listing (i.e., paper copy).

Respectfully submitted,

By:

Richard M. Lebovitz (Reg. No. 37,067)

OriGene Technologies, Inc. 6 Taft Court, Suite 100

Rockville, MD 20850

Filed: October 9, 2001

**Docket No: 16U 102 R1**